p53 expression in biopsies from children with Langerhans cell histiocytosis

被引:22
作者
Bank, MI
Rengtved, P
Carstensen, H
Petersen, BL
机构
[1] Copenhagen Univ Hosp, Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark
[2] Copenhagen Univ Hosp, Dept Pediat, DK-2100 Copenhagen, Denmark
关键词
apoptosis; Langerhans cell histiocytosis; p53;
D O I
10.1097/00043426-200212000-00010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Langerhans cell histiocytosis (LCH) is a rare pediatric and adult disease causing skin rashes, osteolytic bone lesions, tumorous growth in various organs, and in some patients, organ dysfunction. The cause of the disease is obscure, and it is not yet understood why some patients develop single-system lesions only without relapse, whereas others develop fatal multiorgan disease. The expression of p53 tumor suppressor gene product detected immunohistochemically can be used as a guideline to alterations in DNA repair control and apoptosis. The authors have chosen to analyze p53 expression in biopsies from children with LCH and correlate it with clinical manifestation and outcome in a broad range of organs. Patients and Methods: The study was performed on 50 specimens from 32 children (19 boys and 13 girls), median age 3 1/4 years, range 5 months to 12 1/3 years with a definite diagnosis of LCH based on CD1a positivity. The slides were stained with p53 antibody and semiquantitatively evaluated using a grading system from 1 to 5 as an estimate for 0% to 20%, 20% to 40%, 40% to 60%, 60% to 80%, and 80% to 100% p53-positive for pathologic Langerhans cells (pLC), respectively. Results: The p53 protein was expressed in various degrees in pLC in all lesions. The degree of p53 expression could not be correlated to either clinical manifestation or outcome. Conclusions: An increased expression of p53 in pLC indicates an altered DNA repair control with or without abnormal control of apoptosis.
引用
收藏
页码:733 / 736
页数:4
相关论文
共 22 条
  • [1] [Anonymous], 1987, Lancet, V1, P208
  • [2] Current therapy for Langerhans cell histiocytosis
    Broadbent, V
    Gadner, H
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1998, 12 (02) : 327 - +
  • [3] CHU T, 1994, BRIT J CANCER, V70, pS4
  • [4] THE TUMOR-SUPPRESSOR P53
    DONEHOWER, LA
    BRADLEY, A
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1155 (02) : 181 - 205
  • [5] Favara BE, 1997, MED PEDIATR ONCOL, V29, P157, DOI 10.1002/(SICI)1096-911X(199709)29:3<157::AID-MPO1>3.0.CO
  • [6] 2-C
  • [7] TREATMENT STRATEGY FOR DISSEMINATED LANGERHANS CELL HISTIOCYTOSIS
    GADNER, H
    HEITGER, A
    GROIS, N
    GATTERERMENZ, I
    LADISCH, S
    [J]. MEDICAL AND PEDIATRIC ONCOLOGY, 1994, 23 (02): : 72 - 80
  • [8] HYPOXIA INDUCES ACCUMULATION OF P53 PROTEIN, BUT ACTIVATION OF A G(1)-PHASE CHECKPOINT BY LOW-OXYGEN CONDITIONS IS INDEPENDENT OF P53 STATUS
    GRAEBER, TG
    PETERSON, JF
    TSAI, M
    MONICA, K
    FORNACE, AJ
    GIACCIA, AJ
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (09) : 6264 - 6277
  • [9] CELL-CYCLE CONTROL AND CANCER
    HARTWELL, LH
    KASTAN, MB
    [J]. SCIENCE, 1994, 266 (5192) : 1821 - 1828
  • [10] p53: Puzzle and paradigm
    Ko, LJ
    Prives, C
    [J]. GENES & DEVELOPMENT, 1996, 10 (09) : 1054 - 1072